MEI PHARMA, INC. : Change of directors or senior management, financial statements and supporting documents (form 8-K)

Item 5.02 Departure of directors or certain officers; Election of directors;

Appointment of certain officers; Compensatory arrangements of some


Resignation of Director

At 22 November 2021, Sir. Kevan Clemens, member of the Board of Directors (the “Board”) of MEI Pharma, Inc. (the “Company”) resigned from the board with immediate effect.

The decision of Mr. Clemens resigning is not the result of disagreement with the Company on any matter relating to its operations, policies or practices.

Appointment of new director

At 22 November 2021, the Board appointed Mr. Sujay kango fill the vacancy on the Board resulting from the vacancy created by the resignation of Mr. Clemens. Mr. Kango was appointed to the Board of Directors because of his extensive marketing and operational experience. Mr. Kango will serve for the remainder of the term Mr. Clemens and will be a member of the category of directors whose terms each expire at the annual meeting of shareholders of the Company for the financial year 2023, or until his resignation or early dismissal.

Mr. Kango is an experienced executive with over 25 years of experience in the pharmaceutical and biotechnology industries. He has held leadership positions where he was instrumental in building infrastructure and sales teams, while leading several product launches globally. He joined Acceleron Pharma in 2018 where he most recently served as Executive Vice President and Chief Commercial Officer and was responsible for establishing the
North America commercial presence of luspatercept. Mr. Kango has also led several global product launches in several therapeutic areas, including oncology-hematology, rare diseases, immunology and virology. Previously Mr. Kango was Vice President of Global Business Development for Oncology at AbbVie, prior to which he was Executive Vice President and Chief Commercial Officer of Infinity Pharmaceuticals. Mr. Kango also served as Vice President, Global Marketing and Business Operations at Pharmaceutical Onyx, a subsidiary of Amgen. Prior to Onyx, he held several leadership positions including Vice President of Sales and Marketing-Oncology at Merck & Co., Global Business Leader-Procrit® / Eprex® at Ortho-Biotech, and various sales and marketing at Schering-Plow. Mr. Kango obtained a BS in microbiology and an MBA from McNeese State University.

Mr. Kango will participate in the standard compensation package for non-employee directors, including, for his first year on the board, pro-rated annual compensation. As part of his directorial services, Mr. Kango received an initial grant of stock options to purchase 25,000 common shares of the Company, which are subject to vesting over a three-year period, and options to purchase 33,334 common shares of the Company in proportion to the annual allocation of options to July 1, 2021 to all other members of the Plank for fiscal year 2021, under the MEI Pharma, Inc.
Amended and updated 2008 Omnibus share-based compensation plan, which are subject to vesting in monthly installments over a period of twelve months, in each case at an exercise price equal to the closing price of MEI Pharma ordinary shares on 22 November 2021.

There are no related party transactions involving Mr. Kango which are to be declared under Article 404 (a) of Regulation SK. There is no arrangement or understanding between Mr. Kango and any other person under which Mr. Kango was chosen as director. There is no family relationship between the directors, officers and Mr. Kango.

Item 9.01 Financial statements and supporting documents.

(d) Exhibits

Exhibit 99.1      Press release of MEI Pharma, Inc., dated November 23, 2021
                announcing the resignation of Kevan Clemens and the appointment of
                Sujay Kango to the Board of Directors.

104             Cover Page Interactive Data File (embedded within the Inline XBRL

————————————————– ——————————

© Edgar online, source Previews

Comments are closed.